Likes ReceivedThe Stock Connect Hong Kong Innovative Drug ETF Wanjia (520700) surged 3%, with an intraday turnover rate exceeding 17%, and attracted over 43 million in a single day.
On the market, Hong Kong's innovative drug sector surged rapidly, with WuXi XDC rising over 7%, WuXi AppTec rising over 6%, and Ascentage Pharma rising over 4%. As of 10:03, the Stock Connect Innovative Drug ETF (520700) rose 3%, with an intraday turnover rate exceeding 17% and a trading volume reaching 1.4 billion yuan, indicating active market trading.
The Stock Connect Innovative Drug ETF (520700) continues to see capital inflows, with a net inflow of 43.0612 million yuan in the previous trading day. As of the previous trading day, the fund had a total net inflow of 60.7244 million yuan over the past week. Over the past year, the total net inflow reached 672 million yuan.
On the news front, on March 23, WuXi XDC released its 2025 performance report, achieving annual revenue of approximately 59.44 billion yuan, a year-on-year increase of 46.7%; gross profit of approximately 21.39 billion yuan, a year-on-year increase of 72.5%; adjusted net profit attributable to company owners of approximately 15.59 billion yuan, a year-on-year increase of 69.9%; and net profit of 14.8 billion yuan, a year-on-year increase of 38.4%. As of December 31, 2025, the group's total backlog reached 1.489 billion USD, a 50.3% increase from 991 million USD in the same period last year.
On the same day, WuXi AppTec also disclosed its 2025 performance, achieving operating revenue of 454.56 billion yuan, a year-on-year increase of 15.84%; net profit attributable to shareholders of the listed company of approximately 191.51 billion yuan, a year-on-year increase of 102.65%; and net profit attributable to the parent company after deducting non-recurring gains and losses increased by 32.56% year-on-year. The company plans to distribute a cash dividend of approximately 47.12 billion yuan.
Guojin Securities pointed out that the turning point for innovative drug companies to turn losses into profits has arrived, with intensive clinical data catalysts throughout the year, coupled with smooth overseas clinical progress of already out-licensed pipelines, and is optimistic about investment opportunities in the innovative drug sector. The medical device sector as a whole also shows a positive trend, with continuous catalysts from innovative product R&D, steady recovery of domestic demand, and accelerated expansion in overseas markets.
The Stock Connect Innovative Drug ETF (520700) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which has a more scientific and reasonable compilation method, covering leading companies such as BeiGene, Innovent Biologics, and WuXi Biologics. It focuses on listed companies involved in the R&D, production, and services of innovative drugs in the Hong Kong market. Off-market investors can participate in the opportunities of innovative drug development through feeder funds (Class A: 023481; Class C: 023482).
(Funds carry risks, investment requires caution.)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
